Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Evotec's CEO Explains Logic Behind Drug Discovery Pact With Novo Nordisk

Executive Summary

Novo Nordisk's R&D pact with Evotec will open therapeutic possibilities for the Danish group in diabetes and obesity using small molecules, says Evotec's CEO.

You may also be interested in...



Novo Nordisk Cuts 400 Jobs In R&D Reshuffle As It Broadens Its Horizons

Novo, which is under pressure to diversify and signaled plans to cut jobs back in August, will lay off 400 people as it reallocates resources to more efficiently bring in novel products through both R&D and business development, continuing a deal-making spree that's already under way.

Novo Nordisk Grabs Shark Antibody-Based CNS Delivery Technology From Ossianix

Being able to move therapeutic molecules for diabetes and other metabolic diseases into the CNS is the aim of a research collaboration and option agreement between Novo Nordisk and the six-year-old US biotech, Ossianix.

Getting Its ACT Together: EXACT-Tx Raises NOK155m

EXACT-Tx will use funds from a NOK155m private placing to harness ultrasound in precision therapeutic targeting across a variety of indications and product classes.

Topics

Related Companies

UsernamePublicRestriction

Register

SC100339

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel